On October 27, Higer Biotech announced that the first FAK/SRC dual-target inhibitor SIGX1094, which has entered the clinical stage, and the KRAS-G12C inhibitor fluzerecide tablets that have been marketed by Cinda Biotech. The phase II/III clinical trial for KRAS-G12C mutation-positive non-small cell lung cancer has been officially approved by the National Drug Administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.